A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
NCT00584857
Completed
This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy (paclitaxel and carboplatin). This study investigates the effectiveness of the combination of hormonal therapy and chemotherapy. This study also will examine the side-effects associated with these drugs and the quality of life of patients on combination therapy.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
01/25/2017
Locations: UAB Women's and Infant Center, 1700 6th Ave S, Birmingham, Alabama
Conditions: Uterine Cancer
Register for Updates
A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
NCT00584909
Terminated
The main purpose of this study us to determine the best treatment for patients with endometrial cancer who are at an elevated risk for recurrence.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
01/25/2017
Locations: UAB Women's and Infant Center, 1700 6th Avenue South, Birmingham, Alabama
Conditions: Uterine Cancer
Register for Updates
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
NCT00537173
Terminated
This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To date no other trials have analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, we expect that neither genomic or proteomic profiling alone will be sufficient to op... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/24/2017
Locations: Cancer Care Center of Southern Indiana, Bloomington, Indiana +3 locations
Conditions: Breast Cancer
Register for Updates
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
NCT01186991
Completed
This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemoth... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/19/2017
Locations: Comprehensive Blood/Cancer Ctr, Bakersfield, California +52 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
NCT00002931
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with bone marrow transplantation or peripheral stem cell transplantation works in treating patients with relapsed germ cell cancer.
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
01/06/2017
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Register for Updates
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT02311907
Completed
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as glutathione, may help prevent peripheral neuropathy caused by paclitaxel and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2017
Locations: Providence Hospital, Mobile, Alabama +389 locations
Conditions: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Register for Updates
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383148
Terminated
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG401... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +71 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Randomized Amifostine For SCCHN
NCT00095927
Completed
This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2017
Locations: Goodall Hospital, Sanford, Maine +8 locations
Conditions: Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Register for Updates
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00069953
Completed
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells PURPOSE: This phase II trial is studying how well combination chemotherapy followed by chemoradiotherapy, with or without surgery, works in treating patients with resectable locally advanced can... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/30/2016
Locations: Providence Saint Joseph Medical Center - Burbank, Burbank, California +96 locations
Conditions: Esophageal Cancer
Register for Updates
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
NCT00564733
Completed
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC). Drugs used in chemotherapy, such as paclitaxel, carboplatin, gemcitabine hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Diagnostic imaging procedures, such as FDG-labeled PET... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2016
Locations: Harborview Medical Center, Seattle, Washington +1 locations
Conditions: Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT00960960
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) pictilisib administered with letrozole or intravenous (IV) paclitaxel with and without IV bevacizumab or IV trastuzumab in participants with locally recurrent or metastatic breast cancer. The study consists of three parts. Part 1 (pictilisib will be administered in 21+7 schedule along with paclitaxel and/or bevacizumab), Part 2 (pictilisib will be administered... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Not set, Peoria, Illinois +4 locations
Conditions: Breast Cancer
Register for Updates
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
NCT00046514
Completed
The anticancer agent paclitaxel (marketed as Taxol) has shown remarkable activity against metastatic breast cancer. However, the Taxol formulation requires prolonged administration times, and there are safety problems that have been attributed to the solvent rather than the active ingredient, paclitaxel. This is a new formulation of paclitaxel that has been found to have fewer safety problems than Taxol, and may be administered safely at higher doses. This study will investigate the safety and e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Abraxis BioScience, Inc., Raleigh, North Carolina
Conditions: Breast Neoplasms, Metastases, Neoplasm
Register for Updates